company background image
GEN logo

Genomed Spólka Akcyjna WSE:GEN Stock Report

Last Price

zł28.00

Market Cap

zł37.0m

7D

0%

1Y

-30.0%

Updated

21 Jun, 2024

Data

Company Financials

GEN Stock Overview

Provides DNA analysis and congenital diseases diagnostic services in Poland.

GEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Genomed Spólka Akcyjna Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genomed Spólka Akcyjna
Historical stock prices
Current Share Pricezł28.00
52 Week Highzł40.00
52 Week Lowzł28.00
Beta0.0098
11 Month Change0%
3 Month Change-5.41%
1 Year Change-30.00%
33 Year Change-36.36%
5 Year Change12.00%
Change since IPO0%

Recent News & Updates

Recent updates

Would Genomed Spólka Akcyjna (WSE:GEN) Be Valuable To Income Investors?

Mar 03
Would Genomed Spólka Akcyjna (WSE:GEN) Be Valuable To Income Investors?

Is Genomed Spólka Akcyjna's (WSE:GEN) Recent Performancer Underpinned By Weak Financials?

Jan 10
Is Genomed Spólka Akcyjna's (WSE:GEN) Recent Performancer Underpinned By Weak Financials?

Are Dividend Investors Getting More Than They Bargained For With Genomed Spólka Akcyjna's (WSE:GEN) Dividend?

Nov 18
Are Dividend Investors Getting More Than They Bargained For With Genomed Spólka Akcyjna's (WSE:GEN) Dividend?

Shareholder Returns

GENPL BiotechsPL Market
7D0%0.2%3.1%
1Y-30.0%-17.3%21.4%

Return vs Industry: GEN underperformed the Polish Biotechs industry which returned -16.9% over the past year.

Return vs Market: GEN underperformed the Polish Market which returned 19.6% over the past year.

Price Volatility

Is GEN's price volatile compared to industry and market?
GEN volatility
GEN Average Weekly Movementn/a
Biotechs Industry Average Movement5.7%
Market Average Movement5.2%
10% most volatile stocks in PL Market9.0%
10% least volatile stocks in PL Market3.3%

Stable Share Price: GEN has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GEN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200748Anna Boguszewska-Chachulskawww.genomed.pl

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 6,500 genes; and next-generation sequencing technology.

Genomed Spólka Akcyjna Fundamentals Summary

How do Genomed Spólka Akcyjna's earnings and revenue compare to its market cap?
GEN fundamental statistics
Market capzł37.00m
Earnings (TTM)zł521.36k
Revenue (TTM)zł21.73m

71.0x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GEN income statement (TTM)
Revenuezł21.73m
Cost of Revenuezł7.94m
Gross Profitzł13.78m
Other Expenseszł13.26m
Earningszł521.36k

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 13, 2024

Earnings per share (EPS)0.39
Gross Margin63.43%
Net Profit Margin2.40%
Debt/Equity Ratio0%

How did GEN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.